BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 10224355)

  • 1. An in vitro model for the allergen-IgE-FcARI interaction.
    Laffer S; Hogbom E; Adrianson J; Grönlund H; Sillaber C; Valent P; Vangelista L; Kricek F; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):116-8. PubMed ID: 10224355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE.
    Laffer S; Hogbom E; Roux KH; Sperr WR; Valent P; Bankl HC; Vangelista L; Kricek F; Kraft D; Grönlund H; Valenta R
    J Allergy Clin Immunol; 2001 Sep; 108(3):409-16. PubMed ID: 11544461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering, purification and applications of His-tagged recombinant antibody fragments with specificity for the major birch pollen allergen, bet v1.
    Flicker S; Laffer S; Steinberger P; Alhani B; Zhu Y; Laukkanen ML; Keinänen K; Kraft D; Valenta R
    Biol Chem; 2000 Jan; 381(1):39-47. PubMed ID: 10722049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2.
    Vrtala S; Mayer P; Ferreira F; Susani M; Sehon AH; Kraft D; Valenta R
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):913-21. PubMed ID: 8939154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of Bip 1, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1.
    Laffer S; Vangelista L; Steinberger P; Kraft D; Pastore A; Valenta R
    J Immunol; 1996 Dec; 157(11):4953-62. PubMed ID: 8943401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a human IgG4 antibody, BAB2, with specificity for the major Birch pollen allergen, Bet v 1 in Escherichia coli: recombinant BAB2 Fabs enhance the allergic reaction.
    Eibensteiner P; Denépoux S; Steinberger P; Kraft D; Visco V; Banchereau J; Lebecque S; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):190-2. PubMed ID: 10224374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1.
    Lebecque S; Dolecek C; Laffer S; Visco V; Denépoux S; Pin JJ; Guret C; Boltz-Nitulescu G; Weyer A; Valenta R
    J Allergy Clin Immunol; 1997 Mar; 99(3):374-84. PubMed ID: 9058694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgE mimotopes of birch pollen allergen Bet v 1 induce blocking IgG in mice.
    Ganglberger E; Grünberger K; Wiedermann U; Vermes M; Sponer B; Breiteneder H; Scheiner O; Boltz G; Jensen-Jarolim E
    Int Arch Allergy Immunol; 2001; 124(1-3):395-7. PubMed ID: 11307026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergens from birch pollen and pollen of the European chestnut share common epitopes.
    Hirschwehr R; Jäger S; Horak F; Ferreira F; Valenta R; Ebner C; Kraft D; Scheiner O
    Clin Exp Allergy; 1993 Sep; 23(9):755-61. PubMed ID: 10779306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation.
    Villazala-Merino S; Rodriguez-Dominguez A; Stanek V; Campion NJ; Gattinger P; Hofer G; Froeschl R; Fae I; Lupinek C; Vrtala S; Breiteneder H; Keller W; Perkmann T; Nakamura R; Pickl WF; Valenta R; Eckl-Dorna J; Niederberger V
    J Allergy Clin Immunol; 2020 Mar; 145(3):958-967.e5. PubMed ID: 31775017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal IgE antibodies against birch pollen allergens: novel tools for biological characterization and standardization of allergens.
    Kaul S; Scheurer S; Danz N; Schicktanz S; Vieths S; Hoffmann A
    J Allergy Clin Immunol; 2003 Jun; 111(6):1262-8. PubMed ID: 12789227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sensitive assay for the detection of IgE bound to the major birch pollen allergen, Bet v 1, in the form of immune complexes.
    Pree I; Reisinger J; Bohle B; Frantal S; Valenta R; Niederberger V
    J Immunol Methods; 2009 Jun; 345(1-2):100-5. PubMed ID: 19376122
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
    Front Immunol; 2020; 11():2118. PubMed ID: 33013894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses.
    Holm J; Gajhede M; Ferreras M; Henriksen A; Ipsen H; Larsen JN; Lund L; Jacobi H; Millner A; Würtzen PA; Spangfort MD
    J Immunol; 2004 Oct; 173(8):5258-67. PubMed ID: 15470071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
    Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
    Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1.
    Mirza O; Henriksen A; Ipsen H; Larsen JN; Wissenbach M; Spangfort MD; Gajhede M
    J Immunol; 2000 Jul; 165(1):331-8. PubMed ID: 10861069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human blood basophils do not act as antigen-presenting cells for the major birch pollen allergen Bet v 1.
    Kitzmüller C; Nagl B; Deifl S; Walterskirchen C; Jahn-Schmid B; Zlabinger GJ; Bohle B
    Allergy; 2012 May; 67(5):593-600. PubMed ID: 22188598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
    Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
    Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
    Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
    J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.